Gilead prices COVID-19 drug remdesivir at $2340 per patient in developed nations

Patient advocates have argued cost should be lower since remdesivir was developed with financial support from U.S. government. Gilead has agreed to send nearly all of its supply of the drug to US over next 3 months. It is developing an inhaled version for use outside hospital.


Reuters Health